AAA Strengthens European Radiopharmaceutical Manufacturing Network

SAINT GENIS POUILLY, France, February 1, 2013 /PRNewswire/ –

Highlights

        - Acquisition of two well established radiopharmaceutical companies in
          Barcelona, Spain
        - Entry into Polish market following agreement with the University of Warsaw

Advanced Accelerator Applications SA (“AAA”), a fast growing international player in
Molecular Nuclear Medicine (MNM), today announced further expansion of its European
radiopharmaceutical manufacturing network in Spain and Poland. The moves will enable AAA
to enter Poland directly for the first time and strengthens AAA’s leading position in the
Iberian Peninsula.

Acquisition of two radiopharmaceutical companies in Spain

AAA has acquired two well established radiopharmaceutical companies in Barcelona,
Spain: Barnatron and Catalana De Dispensacion, S.A. (Cadisa). Established in 2001,
Barnatron is an authorised manufacturer and distributor of radiopharmaceuticals for
diagnostic use in Positron Emission Tomography (PET). The company’s manufacturing
laboratory is the only one in Spain to have two high-capacity cyclotrons. Barnatron also
works closely with the Experimental Molecular Imaging Centre, conducting research into new
radiopharmaceuticals in collaboration with the Unit of Glycoconjugate Chemistry from the
Spanish National Research Council. For the year ended 2012, Barnatron had sales totaling
EUR2.6 million. Cadisa was established in 1995 and manufactures and supplies
radiopharmaceutical products for Single Photon Emission Tomography (SPECT) to hospitals in
Spain. Its facility is approved by the Nuclear Safety Council and the Ministry of Health
and has the capacity to produce more than 100,000 doses per year. For the year ended 2012,
the company had sales totaling EUR2.6 million.

AAA has existing facilities in Zaragoza and Porto, and one under construction in
Murcia. With the addition of Barnatron and Cadisa, the Company will be able to efficiently
supply the whole of the Iberian Peninsula.

Entry into the Polish market

AAA and its fully owned Polish subsidiary Advanced Accelerator Applications Polska
have signed a long-term collaboration agreement with UWRC SPO KA Z OGRANICZONA
ODPOWIEDZIALNO CIA (UWRC), a fully owned subsidiary of the University of Warsaw, to
manufacture and develop radiopharmaceutical products for the Polish market. Under the
terms of the agreement, AAA will manage the Radiopharmaceutical Production and Research
Centre, located in the Heavy Ion Laboratory at the University of Warsaw, Poland. AAA will
manufacture and supply hospitals in Poland with Gluscan(R), its FluoroDeoxyGlucose (FDG)
tracer and other products. Gluscan(R) is used in PET to image and diagnose a number of
diseases including cancer, CNS and autoimmune disorders. Both UWRC, jointly with the Heavy
Ion Laboratory, and AAA will conduct research in the facilities with the aim of developing
new radiopharmaceutical products.

The University of Warsaw and AAA’s long-term cooperation is based on a shared
conviction of the important growth prospects of the molecular medicine market in Poland.
With approximately 40 million people and less than 20 PET scanners installed, the Polish
market is poised to grow significantly over the next few years.

Stefano Buono, Chief Executive Officer of AAA, said: “The acquisitions of Cadisa and
Barnatronand our recent entry into the Polish market are another step forward in our
strategy to aggressively expand our European radiopharmaceutical manufacturing network.

AAA currently operates 10 European laboratories serving eight countries and has
several others under construction. With the increasing demand for better diagnosis leading
to cost-effective treatment, the MNM market is experiencing significant growth. There are
currently 20 new proprietary F-18 products in clinical development; the first was approved
two weeks ago by the EMA for Alzheimer’s disease. We believe many of the others will reach
the market in the next four to five years and will need to be produced in Europe. PET
tracers are very challenging to manufacture due to their short shelf life of approximately
10 hours. With our specialised European expertise and extensive growing network of
laboratories, we believe we are well-placed to profitably manufacture these molecules for
both existing and new partners.”

About Advanced Accelerator Applications

Advanced Accelerator Applications (http://www.adacap.com), is a European
pharmaceutical company founded in 2002 to develop innovative diagnostic and therapeutic
products. AAA’s main focus is in the field of Molecular Imaging and targeted,
individualised therapy for the management of patients with serious conditions
(Personalized Medicine). AAA currently has 16 production and R&D facilities able to
manufacture both diagnostics and therapeutic MNM products and more than 240 employees in
10 countries (France, Italy, Germany, Switzerland, Spain, Poland, Portugal, Israel, U.S.,
Canada).

In 2011 AAA reported revenues of EUR35.8 million (+20.6% vs. 2010), an EBITDA of
EUR5.94 million and R&D investment and charges in excess of EUR13 million (39% of sales).

SOURCE Advanced Accelerator Applications